Month: January 2024
Rising demand for detecting equipment and increasing adoption of Magnetic Resonance Imaging (MRI) and other medical imaging modalities are key factors driving helium-3 market revenue growth.
Vancouver, Jan. 10, 2024 (GLOBE NEWSWIRE) — The global helium-3 market size was USD 378.0 Million in 2022 and is expected to register a rapid revenue CAGR of 9.0% during the forecast period. Rising demand for detecting equipment and increasing adoption of Magnetic Resonance Imaging (MRI) and other medical imaging modalities are key factors driving market revenue growth.
The global demand for detection equipment is rising rapidly due to increasing popularity of fast neutron spectroscopy measurements, with the demand for helium-3 reaching 65,000litres per year. Most of this demand will be driven by helium detectors used in medical labs, particularly...
Herbal Supplements Market Size Worth USD 172.99 Billion in 2032 | Emergen Research
Written by Customer Service on . Posted in Mergers And Acquisitions.
Increasing disposable income of working population and rising consumer interest in natural and holistic health remedies are key factors driving Herbal Supplements markets revenue growth.
Vancouver, Jan. 10, 2024 (GLOBE NEWSWIRE) — The global herbal supplements market size was USD 86.84 billion in 2022 and is expected to register a rapid revenue CAGR of 7.3% during the forecast period. Increasing disposable income of working population and rising consumer interest in natural and holistic health remedies are key factors driving markets revenue growth.
The rising costs for pharmaceutical and nutritional goods and adverse effects of allopathic medications are other key factors driving revenue growth of the market. Increasing number of health-conscious consumers who are interested in enhancing their well-being are drawn to herbal supplements...
Dry Eye Syndrome Market Size Worth USD 10.55 Billion in 2032 | Emergen Research
Written by Customer Service on . Posted in Mergers And Acquisitions.
Rising demand for effective treatments, and strong R&D investments to support pipeline candidates are expected to drive Dry Eye Syndrome market growth.
Vancouver, Jan. 10, 2024 (GLOBE NEWSWIRE) — The global dry eye syndrome market size was USD 5.32 billion in 2022 and is expected to register a revenue CAGR of 7.3% during the forecast period. Increasing cases of dry eye syndrome across the globe, widespread use of digital devices, such as computers, smartphones, and tablets, numerous Research & Development (R&D) activities by market players, rising demand for effective treatments, and strong R&D investments to support pipeline candidates are expected to drive market revenue growth.
One of the major factors driving revenue growth of the market is increasing number of dry eye syndrome cases due to the excess utilization...
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
Written by Customer Service on . Posted in Public Companies.
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months
Results demonstrated a 61% increase in preventative drug prescriptions among patients in the high-risk group and improved specialist referrals which can significantly reduce overall cost of care and improve patient outcomes
LONDON and SALT LAKE CITY, Jan. 10, 2024 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces publication of Real World Evidence (“RWE”) after 12 months of follow-up in 2,569 patients with Type 2 diabetes and diabetic kidney disease (“DKD”) at a major U.S. health system in Primary Care and Community Health. Results in the diverse cohort, including 27% black patients, demonstrate that electronic health...
OTC Markets Group Welcomes Argentina Lithium & Energy Corp to OTCQX
Written by Customer Service on . Posted in Public Companies.
NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Argentina Lithium & Energy Corp (TSX-V: LIT; OTCQX: LILIF), an alternative fuel material company, has qualified to trade on the OTCQX® Best Market. Argentina Lithium & Energy Corp upgraded to OTCQX from the OTCQB® Venture Market.
Argentina Lithium & Energy Corp begins trading today on OTCQX under the symbol “LILIF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance,...
Mayfair Gold Drills 3.14 g/t Au over 10.0m including 15.94 g/t Au over 1.0m at Fenn-Gib Footwall Zone
Written by Customer Service on . Posted in Public Companies.
Hole FG23-359 reports 27.60 g/t Au over 2.1m, hole FG23-361 intersected 16.47 g/t Au over 2.3m and hole FG23-351 reported 2.19 g/t Au over 16.8m, including 3.28 g/t Au over 7.0 and 3.21 g/t Au over 2.0m
Mineralization outside current Fenn-Gib pit-constrained 3.38M ounce deposit
Footwall Zone structure over 500m strike length, open in all directions
Steep dipping mineralization from surface to below 600m
Multiple parallel mineralized structures intersected
Two drill rigs active at Footwall ZoneVANCOUVER, British Columbia, Jan. 10, 2024 (GLOBE NEWSWIRE) — Mayfair Gold Corp. (“Mayfair” or the “Company”) (TSX-V: MFG; OTCQB: MFGCF) is pleased to announce further results from the higher-grade Footwall Zone located approximately 100 meters (m) to the northwest of the Fenn-Gib gold deposit. Mayfair’s 100% controlled Fenn-Gib Project,...
Arqit announces reseller agreement with Phalanx
Written by Customer Service on . Posted in Public Companies.
LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, today announced a reseller agreement with Phalanx Solutions (Phalanx), a trusted provider of security, compliance and technology solutions, for Arqit’s Symmetric Key Agreement Platform and NetworkSecure™ Adaptor.
Enterprises face growing threats from cyber adversaries and need to take urgent action to strengthen their encryption in the ever-connected world of devices. Easily integrated at modest cost with dynamic rotating authentication, Arqit’s Platform as a Service makes symmetric encryption keys which cannot be broken even by quantum attack. Arqit’s standards-compliant technology is now available to Phalanx’s clients as a deployable solution.
Phalanx Solutions is a leading provider of comprehensive...
Climb Channel Solutions Announces Expanded Partnership with Jamf to Offer Apple Device Management and Protection to US Reseller Partners
Written by Customer Service on . Posted in Public Companies.
EATONTOWN, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) has expanded their partnership with Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, to their US offerings.
The partnership between Jamf and Climb Channel Solutions holds immense value in the realm of technology and business solutions. Jamf, a leading provider of Apple device management and security software, and Climb Channel Solutions, a renowned distributor of innovative technology products, bring together their expertise and resources to deliver exceptional solutions to organizations. This partnership, which has already seen success in Canada, empowers businesses to efficiently manage and secure their Apple...
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
Written by Customer Service on . Posted in Public Companies.
WATERTOWN, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase 2 VERONA clinical trial of EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.
“Dosing the first patient in the Phase 2 VERONA trial represents another significant milestone in advancing our mission to improve the lives of patients with serious retinal diseases. DME is a common sight-threatening complication of diabetes that can lead to severe vision loss. It represents the second diabetic eye...
HBT Financial, Inc. to Announce Fourth Quarter 2024 Financial Results on January 24, 2024
Written by Customer Service on . Posted in Public Companies.
BLOOMINGTON, Ill., Jan. 10, 2024 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT”), the holding company for Heartland Bank and Trust Company, today announced that it will issue its fourth quarter 2024 financial results before the market opens on Wednesday, January 24, 2024. A copy of the press release announcing the fourth quarter 2024 financial results and an investor presentation will be made available on the Company’s investor relations website at https://ir.hbtfinancial.com.
About HBT Financial, Inc.
HBT Financial, Inc., headquartered in Bloomington, Illinois, is the holding company for Heartland Bank and Trust Company, and has banking roots that can be traced back to 1920. HBT provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals,...
